Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 2
A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive s…
Metastatic Salivary Gland CarcinomaRecurrent Salivary Gland CarcinomaStage III Major Salivary Gland Cancer AJCC v8+2 more
Estimated
~$10 – $7,500
NRG OncologyNCT05408845
Phase 2
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally …
Salivary Gland Carcinoma
Estimated
~$10 – $7,500
Manish PatelNCT03942653
Phase 1
A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with adva…
Head and Neck CarcinomaAdenoid Cystic CarcinomaLung Cancer+22 more
Estimated
~$10 – $8,750
Phase 2
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers (I-MAC)
The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the…
Salivary Gland CancerAdvanced Salivary Gland CarcinomaMetastatic Salivary Gland Cancer+1 more
Estimated
~$10 – $7,500
Glenn J. HannaNCT06805617